Skip to main content

uplizna

Generic: inebilizumab-cdon

uplizna: developed by 1 company · 1 FDA decision.

uplizna evidence translation

What we can confirm

What it means

Source-backed records connect uplizna to VIE; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could uplizna → VIE affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Neuromyelitis optica spectrum disorder (NMOSD)

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
Viela Bio, Inc. (VIE)
Neuromyelitis optica spectrum disorder (NMOSD)
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE UPLIZNA is a CD19-directed cytolytic antibody indicated for the treatment of: Neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.1 ) Immunoglobulin G4-related disease (IgG4-RD) in adult patients. ( 1.2 ) Generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. ( 1.2 ) 1.1 Neuromyelitis Optica Spectru(VIE)FDA ↗
BLA761142Type 1 - New Molecular EntityOrphan DrugStandardOtherInjectable

Frequently asked questions

Who is developing uplizna?

uplizna is being developed by Viela Bio, Inc..

What is uplizna's latest FDA decision?

The most recent tracked FDA decision for uplizna is Approval for 1 INDICATIONS AND USAGE UPLIZNA is a CD19-directed cytolytic antibody indicated for the treatment of: Neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.1 ) Immunoglobulin G4-related disease (IgG4-RD) in adult patients. ( 1.2 ) Generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. ( 1.2 ) 1.1 Neuromyelitis Optica Spectru, dated June 11, 2020.